Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Post TAVR Cognitive Function at Short Term: Better or Worse?

Post TAVR Cognitive Function at Short TermThere is little information on the short and mid-term evolution of cognitive function after transcatheter aortic valve replacement (TAVR).

 

The aim of this study was to describe global changes in cognitive function and changes in specific cognitive domains one year after TAVR.

 

Fifty one patients undergoing TAVR, median age 80, were prospectively followed to assess cognitive function using the Montreal Cognitive Assessment Test (MoCA) at baseline, 30 days and one year. Specific cognitive functions (e.g. verbal fluency) were assessed with pertinent tests.

 

Baseline MoCA outcomes, which assesses cognition globally, was 22.71 ± 3.84. Twenty patients (39.2%) showed cognitive decline at baseline, according to test results (<23 of 30 points).

 

MoCA scores improved at short term after TAVR and remained stable at one year (p = 0.022). There were no significant changes over time in specific cognitive domain test outcomes.

 

Conclusion

TAVR improves cognitive function, which is more obvious in patients presenting cognitive decline at baseline. There was also early decline of some specific functions in one quarter of patients that persisted at one year in 10% of these patients.

 

Original Title: Serial Changes in Cognitive Function Following Transcatheter Aortic Valve Replacement.

Reference: Vincent Auffret et al. J Am Coll Cardiol. 2016;68(20):2129-2141.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...